COPD

View All

Pharma News and Updates for BMS, Biogen, Merck, Moderna, and Takeda
Bristol Myers’ Opdivo combo Opdualag for Melanoma; Biogen’s Aduhelm; Marinus’ Ztalmy for CDKL-5 Deficiency Disorder; Merck’s Keytruda + Lynparza; Vitaris’s Breyna; Moderna’s Second COVID-19 Booster Shot; Takeda’s Exkivity; BMS’s First LAG-3 Checkpoint Inhibitor

NHS Grants Fast Track Access to Takeda’s Exkivity Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorisa...

Find More

chronic-respiratory-disease-crd-prevalence-and-treatment-options
Alarming Growth of Chronic Respiratory Diseases (CRDs) and Their Prolonged Impact on the Quality of Life

Today, the increasing prevalence of Chronic Respiratory Diseases (CRDs) is one of the leading health challenges worldwide. CRDs affect hundreds of millions of people and cause huge mortality, morbidity, immense socio-economic burden, and disability-adjusted life years (DALYs).  Over the past few decades, si...

Find More

Nontuberculous Mycobacteria Infection
Lack of effective therapy: A major Nontuberculous Mycobacteria Infection Market Driver

Nontuberculous Mycobacteria (NTM) is a ubiquitous, aerobic, non-motile, acid-fast bacteria, which, when inhaled, may cause severe lung disorders. Especially common in the elderly, individuals with lung diseases, slender caucasian women, and people with esophageal disorders, NTM affects both healthy persons and thos...

Find More

Chronic Obstructive Pulmonary Disease (COPD ) Treatment Market
Is Air Pollution a driver in COPD Treatment Market?

Levels of air pollution have risen dramatically over the past years due to increasing outdoor human activities such as industrialization, urbanization and indoor activities like burning of solid fuels, coal, etc. This has contaminated the air we breathe with several harmful substances such as Sulfur dioxide (SO2), ...

Find More

WORLD CHRONIC OBSTRUCTIVE PULMONARY DISEASE DAY

[caption id="attachment_3632" align="aligncenter" width="1387"]                                                                                                     COPD[/caption] Chronic obstructive pulmonary disease ( COPD ) is a chronic inflammatory lung disease that causes obstructed airflow from the lung...

Find More

transthyretin amyloidosis
Notizia

Nucala of GlaxoSmithKline exhibits splendid benefits to other IL-5 Inhibitors in Asthma, however flunks as a COPD Drug A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala, which targets the IL-5 pathway, was initially appro...

Find More

cancer
Clinical

Use of Placebo is Necessary Only in Certain Types of Oncology Trials: USFDA In a new draft guidance released, the USFDA is questioning whether or not the use of a placebo in a double-blind, randomized clinical trial is always necessary. The FDA said sometimes the use of a placebo can present practical or ethical co...

Find More

Delveinsight
Chronic Obstructive Pulmonary Disorder

[caption id="attachment_1860" align="aligncenter" width="1890"] Chronic Obstructive Pulmonary Disorder[/caption]

Find More

Chronic Obstructive Pulmonary Disease (COPD): Scenario

Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening lung disease which leads to airflow limitation and interferes with normal breathing. According to World Health Organization, approximately 64 million people are affected by COPD worldwide. World Health Organization estimates Chronic Obstr...

Find More

AstraZeneca’s new Asthma Drug Aces Phase III trial

AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year. The drug, Benralizumab, is a new biological treatment for people with severe asthma, and works by targeting eosinophils that cause inflammation in the lungs of ...

Find More